rifadin
sanofi s.r.l. - rifampicina - rifampicina
rifinah
sanofi s.r.l. - rifampicina, associazioni - rifampicina, associazioni
ciprofloxacina pharmacare
pharmacare s.r.l. - ciprofloxacina - ciprofloxacina
ciprofloxacina doc generici
doc generici srl - ciprofloxacina - ciprofloxacina
ciprosol
baxter holding bv - ciprofloxacina - ciprofloxacina
rifater
sanofi s.r.l. - rifampicina, pirazinamide e isoniazide - rifampicina, pirazinamide e isoniazide
rimactazid
sandoz s.p.a. - rifampicina, associazioni - rifampicina, associazioni
rimcure
sandoz s.p.a. - rifampicina, pirazinamide e isoniazide - rifampicina, pirazinamide e isoniazide
rimstar
sandoz s.p.a. - rifampicina, pirazinamide, etambutolo e isoniazide - rifampicina, pirazinamide, etambutolo e isoniazide
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.